Flexion Therapeutics

Renovacor Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 12, 2022
Pharmaceutical, Genetics, Health, Cardiology, Company, Disease, U.S. Securities and Exchange Commission, Research, Patient, DCM, Public expenditure, Quality of life, Therapy, Flexion Therapeutics, COVID-19, Continuous Progress Mathematics, RCOR, Industry, Intellectual property, Forward-looking statement, Heart failure, Sale, Private Securities Litigation Reform Act, Securities & Exchange Commission of Pakistan, CFO, NYSE, Second Half, Pharmaceutical industry, Online gambling, IND

Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today reported financial results for the first quarter of 2022 and provided a corporate update.

Key Points: 
  • Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today reported financial results for the first quarter of 2022 and provided a corporate update.
  • Strengthened Executive Team with the Appointment of Fred Driscoll as Chief Financial Officer (CFO): Mr. Driscoll joined Renovacor with over 25 years of executive experience in the biotech industry.
  • Opened New Company Headquarters in Cambridge, Massachusetts: New space supports companys growth and provides access to strong regional talent pool.
  • Net income for the three months ended March 31, 2022 was $6.6 million, compared to net loss of $1.7 million for the same period in 2021.

Everly Health Names Dr. Liz Kwo as Chief Medical Officer

Retrieved on: 
Monday, March 28, 2022
Well, Therapy, BA, Cambridge Health Alliance, Population, Data science, Health, Automation, Occupational medicine, Nursing, Multimedia, American Well, General manager, MPH, Harvard University, Harvard T.H. Chan School of Public Health, Anthem, CEO, Public health, MD, Independent Healthcare Providers Network, Artificial intelligence, Cheek, MBA, Harvard Medical School Center for Health and the Global Environment, Harvard Medical School, Harvard Business School, Physician, Flexion Therapeutics, Solution, Electronics, Founder, Research, Technology, Patient, Management, Medical device, Natalism, Stanford University

AUSTIN, Texas, March 28, 2022 /PRNewswire/ -- Today Everly Health announced thehire of Dr. Liz Kwo, MD, MBA, MPH, as the company's Chief Medical Officer effective immediately.

Key Points: 
  • AUSTIN, Texas, March 28, 2022 /PRNewswire/ -- Today Everly Health announced thehire of Dr. Liz Kwo, MD, MBA, MPH, as the company's Chief Medical Officer effective immediately.
  • Dr. Kwo brings a deep expertise and innovation leadership in data science, automation and artificial intelligence for digital health.
  • Before joining Everly Health, Dr. Kwo most recently served as Deputy Chief Clinical Officer for Anthem and helped modernize disease management and care delivery for more than 40 million Americans.
  • Headquartered in Austin, Texas, Everly Health is the parent company to Everlywell, Everly Health Solutions, Natalist, and Everly Diagnostics.

Immunovant Appoints Mark Levine as Chief Legal Officer

Retrieved on: 
Tuesday, January 25, 2022
U.S. Securities and Exchange Commission, Negotiation, Compliance, Clinical Data Interchange Standards Consortium, Nasdaq, SUNY, Calendar, General counsel, COVID-19, Binghamton University, SEC, Immunoglobulin G, Washington University School of Law, Degenerative disease, TED, WAIHA, Therapy, Graves' ophthalmopathy, MG, Anatomical terms of motion, Private Securities Litigation Reform Act, Company, Corporation, Annual report, Security (finance), Acquisition, Flexion Therapeutics, Patient, FDA, AbbVie, Myasthenia gravis, Forest Laboratories, GLOBE, Associate, Safety, Pharmaceutical industry, Vaccine

NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced the appointment of Mark Levine as Chief Legal Officer.

Key Points: 
  • NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced the appointment of Mark Levine as Chief Legal Officer.
  • We are extremely pleased to welcome Mark Levine as Immunovants Chief Legal Officer, saidPete Salzmann, M.D., Chief Executive Officer.
  • Mr. Levine joins Immunovant with more than 20 years of legal experience including negotiating mergers, acquisitions, and divestitures; managing licensing agreements and partnerships; and providing counsel to optimize development and commercialization.
  • Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer

Retrieved on: 
Monday, December 20, 2021
FNCH, Therapy, U.S. Securities and Exchange Commission, Food, University School, Law, Doctor of Philosophy, Inflammatory bowel disease, Private Securities Litigation Reform Act, Industry, Bachelor of Arts, COVID-19, CDI, SEC, Northeastern University School of Law, Breakthrough therapy, Clostridioides difficile (bacteria), General counsel, Corporation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Marketing, Patient, AMAG Pharmaceuticals, Security (finance), Leadership, Autism, Patent, GLOBE, Takeda, Partnership, Tufts University, Flexion Therapeutics, Clostridioides difficile infection, Technology, JD, Pharmaceutical industry, Finch

SOMERVILLE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Finch or Finch Therapeutics) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced the promotion of Joseph Vittiglio, JD, to Chief Business and Legal Officer.

Key Points: 
  • SOMERVILLE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Finch or Finch Therapeutics) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced the promotion of Joseph Vittiglio, JD, to Chief Business and Legal Officer.
  • Joes breadth of experience building successful biotech companies and catalyzing strategic partnerships is invaluable to Finch as we continue to advance our platform and expand our pipeline of microbiome product candidates, said Mark Smith, PhD, Chief Executive Officer of Finch Therapeutics.
  • Prior to Finch, Mr. Vittiglio was the General Counsel and Chief Business Officer for AMAG Pharmaceuticals, where he led the companys legal and business development initiatives, including multiple out-licensing and partnership collaborations, and provided oversight for multiple therapeutic product launches.
  • Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs.

Pacira BioSciences Announces Closing of $375 Million Five-Year Term Loan B

Retrieved on: 
Thursday, December 9, 2021
U.S. Securities and Exchange Commission, New Drug Application, Risk, GLOBE, Chronic pain, Growth, Flexion Therapeutics, Security (finance), Spasticity, Bupivacaine, Bookrunner, Term loan, Private Securities Litigation Reform Act, Chase Bank, Patient, Anatomical terms of motion, Industry, Therapy, Sympathetic nervous system, Osteoarthritis, LLC, COVID-19, Senior, Food and Drug Administration, JPMorgan Chase, Patent, Marketing, Annual report, Acquisition, Bank

TAMPA, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the closing of a $375 million Senior Secured Term Loan B Facility.

Key Points: 
  • TAMPA, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the closing of a $375 million Senior Secured Term Loan B Facility.
  • We believe this successful debt offering provides further validation of the strength of our forecasted earnings and operating cash flow.
  • We remain confident in our five-year plan to achieve robust revenue and earnings expansion, said Charles Reinhart, chief financial officer of Pacira BioSciences.
  • The Term Loan B was placed with high-quality institutional lenders.

Pacira BioSciences Reports Preliminary Net Product Sales of $44.3 Million for October 2021

Retrieved on: 
Tuesday, November 9, 2021
Molecule, Industry, Therapy, Constipation, Security (finance), Swelling, Safety, Growth, Freezing, COVID-19, Spine, Acquisition, Pain, Bruise, Flexion Therapeutics, Nervous system, Analgesic, Risk, Erythema, Cryoglobulinemia, Tenderness, Joint, Failure, Vomiting, U.S. Securities and Exchange Commission, Bupivacaine, GLOBE, Peri, Fever, Red, Time, Marketing, Patent, Patient, Cold urticaria, Ice, Pregnancy, Private Securities Litigation Reform Act, Edema, Time-invariant system, Liver disease, Inflammation, Vein, Osteoarthritis, Vaccine, Central nervous system, New Drug Application, Child, Paroxysmal cold hemoglobinuria, Sensation, Liposome, Nausea, Allergy, Fasciculation, Annual report, Knee, Food and Drug Administration, Nasdaq, Animal, Pharmaceutical industry

TAMPA, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales.

Key Points: 
  • TAMPA, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales.
  • EXPAREL (bupivacaine liposome injectable suspension) net product sales of $42.5 million for the month of October 2021, compared with $40.7 million for the prior year.
  • Net product sales of iovera were $1.2 million for the month of October 2021, compared with $1.0 million for the prior year.
  • To provide greater transparency, the company is reporting monthly intra-quarter unaudited net product sales until it has gained enough visibility around the impacts of COVID-19.

Alentis Therapeutics Announces Appointments of Luca Santarelli to the Board of Directors and Rafaèle Tordjman as Chairperson

Retrieved on: 
Tuesday, November 9, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, NCNA, University, University of Strasbourg, CLDN1, LYS, Therapy, Ecosystem, Tissue, MD, Pfizer, DBV Technologies, Kidney, CEO, NASDAQ, Doctor of Philosophy, Roche, Disease, Founder, Growth, Faricimab, Non-executive director, Investment, Diabetic retinopathy, Sofinnova, HIV disease progression rates, National Institute, Founder CEO, Board, Chairperson, Company, IPO, Board of directors, Flexion Therapeutics, Cirrhosis, Pathology, Fibrosis, Lung, Luca, Gedeon Richter, Patient, Pharmaceutical industry

Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today the appointments of Luca Santarelli, M.D.

Key Points: 
  • Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today the appointments of Luca Santarelli, M.D.
  • PhD as Chairperson of its Board of Directors, with immediate effect.
  • Dr. Luca Santarelli is a physician scientist and an entrepreneurial pharmaceutical executive with more than 20 years experience in academic and industrial R&D and business development.
  • Dr. Rafale Tordjman, MD, PhD is a highly experienced investor with more than 25 years experience in the life sciences.

Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 4, 2021
Safety, Acinetobacter, Entasis, Gram, Failure, Test, Ceftriaxone, Infection, Patient, Marketing, Insurance, Pseudomonas aeruginosa, Private Securities Litigation Reform Act, Nephrotoxicity, U.S. Securities and Exchange Commission, Data, National Rural Development Partnership, Leadership, Colistin, Forward-looking statement, Nature, Company, Clinical trial, Webcast, Cooperative, Diversified Specialty Institute Holdings, Inc., NDA, News, Wellcome Trust, Gonorrhea, Nasdaq, Research, Mortality, Therapy, Flexion Therapeutics, GLOBE, Population, Pharmaceutical industry, Management, Vaccine

Mortality analyses in all pre-specified populations included in the topline results unequivocally favored SUL-DUR versus colistin.

Key Points: 
  • Mortality analyses in all pre-specified populations included in the topline results unequivocally favored SUL-DUR versus colistin.
  • Ms. Triolapreviously served as the Vice President, Marketing at Summit Therapeutics, and prior to that held leadership roles at Flexion Therapeutics, Chiasma, Cubist, and Biogen.
  • As of September 30, 2021, cash and cash equivalents were $44.1 million, compared to $53.2 million as of December 31, 2020.
  • The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GWB, COLB, FTSI, FLXN; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Monday, November 1, 2021
GWB, COLB, Fraud, NASDAQ, NYSE, First Interstate, Flexion Therapeutics, LLC, Umpqua Holdings Corporation, First Interstate BancSystem, Advertising, Great Western, Therapy, GLOBE, Sale, Security (finance)

If you are a Great Western shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Great Western shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options.
  • Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ESBK, FLXN, COLB, CXP; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Friday, October 22, 2021
Community Bank, N.A., COLB, Fraud, NASDAQ, NYSE, Flexion Therapeutics, Umpqua Holdings Corporation, Advertising, Therapy, CXP, GLOBE, Sale, Security (finance)

If you are a Flexion shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Flexion shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options.
  • Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.